BioMed Realty has added Cyclerion Therapeutics to the tenant roster of 301 Binney St. in Cambridge, Mass. The biotech company has signed a 114,454-square-foot lease shortly after it announced its tax-free public spin-off from Ironwood Pharmaceuticals.
The property encompasses a total of 417,290 square feet across five stories, which include 208,645 square feet of laboratory space. Completed in 2008, it underwent renovations in 2013, which resulted in a reimagined lobby and a new café. Additionally, the Class A asset features flexible floorplans, conference room and a shared underground parking garage. The property is fully occupied, with the other tenants being Synlogic, Biogen and Living Proof Inc., Yardi Matrix data shows.
Located on 2.5 acres in the city’s East Cambridge neighborhood, the building sits minutes away from the MIT campus. It is also close to two subway stations, a bus stop and Interstate 93. Logan International Airport is a 10-minute drive away.
“We are excited that Cyclerion will be situated in the heart of the Kendall Square biopharma innovation district,” Cyclerion Therapeutics CEO Peter Hecht said in a prepared statement.
Last month, BioMed Realty acquired a Bay Area office property in a sale-leaseback deal.